ODAC to review Evista
FDA's Oncology Drug Advisory Committee will review Lilly's Evista (raloxifene) for reduction in the risk of invasive breast cancer in postmenopausal women at high risk for breast cancer and those with osteoporosis July 24. Evista is approved for treatment and prevention of osteoporosis in postmenopausal women, which may help raloxifene gain ground in the cancer prevention market (1"The Pink Sheet" June 11, 2007, p. 14). GPC's satraplatin will also be discussed (2"The Pink Sheet" May 21, 2007, In Brief)...
You may also be interested in...
Physician experience in treating osteoporosis patients with Lilly's Evista (raloxifene) might improve the product's uptake for reducing the risk of breast cancer
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.